1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/13/2024 | HAE | Buy Now | Haemonetics | $75.79 | 38.54% | Barrington Research | Michael Petusky | → $105 | Reiterates | Outperform → Outperform | Get Alert |
11/03/2023 | HAE | Buy Now | Haemonetics | $75.79 | 38.54% | Barrington Research | Michael Petusky | $114 → $105 | Maintains | Outperform | Get Alert |
10/02/2023 | HAE | Buy Now | Haemonetics | $75.79 | 24.03% | Citigroup | Joanne Wuensch | $90 → $94 | Maintains | Neutral | Get Alert |
08/09/2023 | HAE | Buy Now | Haemonetics | $75.79 | 50.42% | Barrington Research | Michael Petusky | $111 → $114 | Maintains | Outperform | Get Alert |
05/12/2023 | HAE | Buy Now | Haemonetics | $75.79 | 46.46% | Barrington Research | Michael Petusky | $103 → $111 | Maintains | Outperform | Get Alert |
05/12/2023 | HAE | Buy Now | Haemonetics | $75.79 | 26.67% | Morgan Stanley | Drew Ranieri | $88 → $96 | Maintains | Equal-Weight | Get Alert |
05/12/2023 | HAE | Buy Now | Haemonetics | $75.79 | 51.74% | JMP Securities | David Turkaly | $105 → $115 | Maintains | Market Outperform | Get Alert |
02/08/2023 | HAE | Buy Now | Haemonetics | $75.79 | 16.11% | Morgan Stanley | Drew Ranieri | $84 → $88 | Maintains | Equal-Weight | Get Alert |
02/08/2023 | HAE | Buy Now | Haemonetics | $75.79 | 25.35% | Citigroup | Joanne Wuensch | $92 → $95 | Maintains | Neutral | Get Alert |
02/08/2023 | HAE | Buy Now | Haemonetics | $75.79 | 35.9% | Barrington Research | Michael Petusky | $94 → $103 | Maintains | Outperform | Get Alert |
02/08/2023 | HAE | Buy Now | Haemonetics | $75.79 | 51.74% | Mizuho | Anthony Petrone | $110 → $115 | Maintains | Buy | Get Alert |
01/24/2023 | HAE | Buy Now | Haemonetics | $75.79 | 45.14% | Mizuho | Anthony Petrone | $100 → $110 | Maintains | Buy | Get Alert |
01/06/2023 | HAE | Buy Now | Haemonetics | $75.79 | 10.83% | Morgan Stanley | Drew Ranieri | $90 → $84 | Maintains | Equal-Weight | Get Alert |
12/12/2022 | HAE | Buy Now | Haemonetics | $75.79 | 21.39% | Citigroup | Joanne Wuensch | $88 → $92 | Maintains | Neutral | Get Alert |
11/08/2022 | HAE | Buy Now | Haemonetics | $75.79 | 24.03% | Barrington Research | Michael Petusky | $88 → $94 | Maintains | Outperform | Get Alert |
11/08/2022 | HAE | Buy Now | Haemonetics | $75.79 | 18.75% | Morgan Stanley | Drew Ranieri | $85 → $90 | Maintains | Equal-Weight | Get Alert |
11/08/2022 | HAE | Buy Now | Haemonetics | $75.79 | 31.94% | Mizuho | Anthony Petrone | $90 → $100 | Maintains | Buy | Get Alert |
11/08/2022 | HAE | Buy Now | Haemonetics | $75.79 | 38.54% | JMP Securities | David Turkaly | $90 → $105 | Maintains | Market Outperform | Get Alert |
11/08/2022 | HAE | Buy Now | Haemonetics | $75.79 | 31.94% | Raymond James | Andrew Cooper | $88 → $100 | Maintains | Outperform | Get Alert |
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on February 13, 2024. The analyst firm set a price target for $105.00 expecting HAE to rise to within 12 months (a possible 38.54% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Haemonetics (NYSE: HAE) was provided by Barrington Research, and Haemonetics reiterated their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on February 13, 2024 so you should expect the next rating to be made available sometime around February 13, 2025.
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a reiterated with a price target of $0.00 to $105.00. The current price Haemonetics (HAE) is trading at is $75.79, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.